First Trust Advisors Reduces Biogen Stake by 3.8%

Institutional investor sells 33,266 shares of biotechnology company

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

First Trust Advisors LP reduced its stake in Biogen Inc. (NASDAQ:BIIB) by 3.8% during the third quarter, according to the company's 13F filing with the Securities & Exchange Commission. The institutional investor now owns 840,557 shares of the biotechnology company's stock, valued at $117,745,000.

Why it matters

This transaction highlights the shifting investment landscape around Biogen, as major institutional investors adjust their positions in the company. Biogen's stock performance and pipeline developments are closely watched by the investment community.

The details

In the third quarter, First Trust Advisors sold 33,266 shares of Biogen, reducing its overall stake in the company by 3.8%. The institutional investor now owns 840,557 shares of Biogen, valued at $117,745,000.

  • The transaction occurred during the third quarter of the year.

The players

First Trust Advisors LP

An American investment management firm that provides a variety of financial products and services.

Biogen Inc.

A multinational biotechnology company focused on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases.

Got photos? Submit your photos here. ›

The takeaway

This transaction reflects the ongoing shifts in institutional investment strategies around Biogen, as major players adjust their positions in the company. The biotechnology sector continues to be a closely watched area for investors seeking exposure to innovative medical treatments.